

Justin R Bailey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/337012/publications.pdf>

Version: 2024-02-01

42
papers

2,715
citations

218677

26
h-index

276875

41
g-index

46
all docs

46
docs citations

46
times ranked

3204
citing authors

#	ARTICLE	IF	CITATIONS
1	Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4 ⁺ T Cells. <i>Journal of Virology</i> , 2006, 80, 6441-6457.	3.4	377
2	Maintenance of viral suppression in HIV-1 ⁺ infected HLA-B*57+ elite suppressors despite CTL escape mutations. <i>Journal of Experimental Medicine</i> , 2006, 203, 1357-1369.	8.5	250
3	Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. <i>Hepatology</i> , 2014, 59, 2140-2151.	7.3	230
4	Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. <i>Gastroenterology</i> , 2019, 156, 418-430.	1.3	162
5	Neutralizing Antibodies Do Not Mediate Suppression of Human Immunodeficiency Virus Type 1 in Elite Suppressors or Selection of Plasma Virus Variants in Patients on Highly Active Antiretroviral Therapy. <i>Journal of Virology</i> , 2006, 80, 4758-4770.	3.4	156
6	Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. <i>JCI Insight</i> , 2017, 2, .	5.0	129
7	HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. <i>Cell Host and Microbe</i> , 2018, 24, 703-716.e3.	11.0	95
8	Transmission of Human Immunodeficiency Virus Type 1 from a Patient Who Developed AIDS to an Elite Suppressor. <i>Journal of Virology</i> , 2008, 82, 7395-7410.	3.4	90
9	Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. <i>Cell Host and Microbe</i> , 2018, 24, 717-730.e5.	11.0	78
10	Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. <i>Journal of Clinical Investigation</i> , 2015, 125, 437-447.	8.2	78
11	Durable SARS-CoV-2 B cell immunity after mild or severe disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	76
12	Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV. <i>Aids</i> , 2021, 35, 2399-2401.	2.2	76
13	A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 1253-1260.	4.7	73
14	CMPK2 and BCL-G are associated with type 1 interferon ⁺ induced HIV restriction in humans. <i>Science Advances</i> , 2018, 4, eaat0843.	10.3	64
15	Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice. <i>Hepatology</i> , 2016, 64, 1922-1933.	7.3	60
16	Evidence of CD8 ⁺ T-Cell-Mediated Selective Pressure on Human Immunodeficiency Virus Type 1 in HLA-B*57 ⁺ Elite Suppressors. <i>Journal of Virology</i> , 2009, 83, 88-97.	3.4	59
17	Evolution of HIV-1 in an HLA-B*57 ⁺ Positive Patient during Virologic Escape. <i>Journal of Infectious Diseases</i> , 2007, 196, 50-55.	4.0	55
18	Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs. <i>Current Opinion in Immunology</i> , 2004, 16, 470-476.	5.5	53

#	ARTICLE	IF	CITATIONS
19	Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E82-E91.	7.1	52
20	A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response. <i>Transplantation</i> , 2022, 106, 1440-1444.	1.0	49
21	Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1. <i>PLoS Pathogens</i> , 2017, 13, e1006235.	4.7	47
22	No recovery of replication-competent HIV-1 from human liver macrophages. <i>Journal of Clinical Investigation</i> , 2018, 128, 4501-4509.	8.2	41
23	Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?. <i>Trends in Microbiology</i> , 2018, 26, 854-864.	7.7	39
24	Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2. <i>Journal of Virology</i> , 2019, 93, .	3.4	37
25	Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance. <i>Journal of Clinical Investigation</i> , 2019, 129, 4786-4796.	8.2	33
26	Factors Associated With the Control of Viral Replication and Virologic Breakthrough in a Recently Infected HIV-1 Controller. <i>EBioMedicine</i> , 2017, 16, 141-149.	6.1	27
27	Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles. <i>Journal of General Virology</i> , 2016, 97, 2883-2893.	2.9	27
28	A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies. <i>Journal of Virology</i> , 2016, 90, 3773-3782.	3.4	24
29	Constraints on Viral Evolution during Chronic Hepatitis C Virus Infection Arising from a Common-Source Exposure. <i>Journal of Virology</i> , 2012, 86, 12582-12590.	3.4	23
30	IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. <i>JCI Insight</i> , 2022, 7, .	5.0	23
31	An ultralong CDRH2 in HCV neutralizing antibody demonstrates structural plasticity of antibodies against E2 glycoprotein. <i>ELife</i> , 2020, 9, .	6.0	21
32	An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development. <i>Gastroenterology</i> , 2022, 162, 562-574.	1.3	20
33	Acute Hepatitis C Virus Infection Induces Consistent Changes in Circulating MicroRNAs That Are Associated with Nonlytic Hepatocyte Release. <i>Journal of Virology</i> , 2015, 89, 9454-9464.	3.4	19
34	Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp). <i>Methods in Molecular Biology</i> , 2019, 1911, 441-450.	0.9	17
35	Defining Breadth of Hepatitis C Virus Neutralization. <i>Frontiers in Immunology</i> , 2018, 9, 1703.	4.8	12
36	B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection. <i>PLoS Pathogens</i> , 2022, 18, e1010179.	4.7	6

#	ARTICLE	IF	CITATIONS
37	Mechanisms of HCV resistance to broadly neutralizing antibodies. <i>Current Opinion in Virology</i> , 2021, 50, 23-29.	5.4	5
38	Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	5
39	Broadly neutralizing antibodies against hepatitis C virus: location, location, location. <i>Journal of Hepatology</i> , 2020, 72, 604-606.	3.7	4
40	Decreased Activated CD4 ⁺ T Cell Repertoire Diversity After Antiretroviral Therapy in HIV-1/HCV Coinfection Correlates with CD4 ⁺ T Cell Recovery. <i>Viral Immunology</i> , 2021, 34, 622-631.	1.3	2
41	Planning for the HPV Vaccine and Its Impact on Cervical Cancer Prevention. <i>Comprehensive Therapy</i> , 2006, 32, 102-105.	0.2	1
42	Antiretroviral therapy for HIV and intrahepatic hepatitis C virus replication. <i>Aids</i> , 2021, Publish Ahead of Print, .	2.2	1